Goldman Sachs Group Inc. trimmed its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 20.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,449 shares of the biopharmaceutical company’s stock after selling 11,415 shares during the period. Goldman Sachs Group Inc. owned approximately 0.08% of Dynavax Technologies Corporation worth $429,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. GMT Capital Corp lifted its holdings in shares of Dynavax Technologies Corporation by 28.2% during the 2nd quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after buying an additional 660,637 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Dynavax Technologies Corporation by 10.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after buying an additional 199,004 shares during the period. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Dynavax Technologies Corporation by 4.0% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock valued at $11,024,000 after buying an additional 43,850 shares during the period. C WorldWide Group Holding A S lifted its holdings in shares of Dynavax Technologies Corporation by 135.2% during the 2nd quarter. C WorldWide Group Holding A S now owns 668,215 shares of the biopharmaceutical company’s stock valued at $6,448,000 after buying an additional 384,133 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Dynavax Technologies Corporation by 23.7% during the 1st quarter. Renaissance Technologies LLC now owns 574,051 shares of the biopharmaceutical company’s stock valued at $3,416,000 after buying an additional 110,100 shares during the period. Institutional investors and hedge funds own 58.55% of the company’s stock.

Dynavax Technologies Corporation (DVAX) opened at $18.13 on Wednesday. Dynavax Technologies Corporation has a twelve month low of $3.70 and a twelve month high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business’s quarterly revenue was down 68.8% on a year-over-year basis. During the same period last year, the firm earned ($0.90) earnings per share. equities research analysts anticipate that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dynavax Technologies Corporation (DVAX) Holdings Reduced by Goldman Sachs Group Inc.” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-holdings-reduced-by-goldman-sachs-group-inc/1704108.html.

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald increased their price target on Dynavax Technologies Corporation from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Thursday, November 9th. Cowen and Company reissued a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Friday, November 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 price target (up from $26.00) on shares of Dynavax Technologies Corporation in a report on Monday, September 25th. ValuEngine raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, William Blair reissued an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $25.17.

Dynavax Technologies Corporation Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.